Operational Summary

for the Fiscal Year Ended March 31, 2021

May 12, 2021

Mitsubishi Chemical Holdings Corporation

Table of Contents

Consolidated Financial Statements for FY2020

Statements of Operations

Sales Revenue and Core Operating Income by Business Segment

Analysis of Core Operating Income

Overview of Business Segments

Special Items

Cash Flows

Statements of Financial Positions

FY2021 Forecasts

Business Segments : Changes from Fiscal 2020

Business Segment Information

Statement of Operations

Sales Revenue and Core Operating Income

Dividend Forecast

Page No.

References 1

Number of Subsidiaries and Affiliates and

5

Overseas Sales Revenue and Core Operating

Income

6

Statements of Operations [Quarterly Data]

7

Sales Revenue and Core Operating Income

by Business Segment [Quarterly Data]

8

Core Operating Income (Loss) by Business

Segment [New Business Segment basis]

  1. Special Items [Quarterly Data]
    Capital Expenditure, Depreciation & Amortization,
  2. R&D Expenses, and Number of Employees by Business Segment
  3. Trend of Performance

Page No. Trend of Financial Position

16

References 2

18 Consolidated financial results for the Fiscal Year Ended March 31, 2021 (MTPC)

19

20

21

Page No.

23

24

25

26

27

28

29

30

Page No.

32

Mitsubishi Chemical Holdings Corporation has adopted IFRS starting with FY2016 1Q.

2

List of Abbreviations

FY2021

April 1, 2021 - March 31, 2022

1st Half (1H):

April 1, 2021 - September 30, 2021

2nd Half (2H):

October 1, 2021 - March 31, 2022

FY2020

April 1, 2020 - March 31, 2021

1st Quarter (1Q):

April 1, 2020 - June 30, 2020

2nd Quarter (2Q):

July 1, 2020 - September 30, 2020

3rd Quarter (3Q):

October 1, 2020 - December 31, 2020

4th Quarter (4Q):

January 1, 2021 - March 31, 2021

1st Half (1H):

April 1, 2020 - September 30, 2020

2nd Half (2H):

October 1, 2020 - March 31, 2021

FY2019

April 1, 2019 - March 31, 2020

MCHC

Mitsubishi Chemical Holdings Corporation

MCC

Mitsubishi Chemical Corporation

MTPC

Mitsubishi Tanabe Pharma Corporation

LSII

Life Science Institute, Inc.

NSHD

Nippon Sanso Holdings Corporation

3

Core Operating Income (Loss) by Business Segment

[Quarterly Data]

(Billions of Yen)

100.0

77.6

80.0

70.1

61.1

60.7

59.0

60.0

49.3

50.2

39.6

40.0

20.0

13.8 15.0

0.0

(20.0)

3Q

4Q

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

FY2018

FY2019

FY2020

Performance Products

Chemicals

Industrial Gases

Health Care

Others

4

Consolidated Statements of Operations

Exchange Rate (¥/$)

106.3

105.6

105.9

109.0

(3.1)

(3%)

Naphtha Price (¥/kl)

27,600

35,000

31,300

42,900

(11,600)

(27%)

(Billions of Yen)

FY2020

FY2019

Difference

1H

2H

%

Sales Revenue

1,504.8

1,752.7

3,257.5

3,580.5

(323.0)

(9%)

Continuing

Core Operating Income *1

54.6

120.1

174.7

194.8

(20.1)

(10%)

Special Items

(82.7)

(44.5)

(127.2)

(50.5)

(76.7)

Operating Income (Loss)

(28.1)

75.6

47.5

144.3

(96.8)

(67%)

*Operations

Financial Income/Expenses

(8.7)

(5.9)

(14.6)

(22.3)

7.7

Income Taxes

(3.1)

(7.1)

(10.2)

(52.3)

42.1

(Dividend included above)

[2.8]

[1.5]

[4.3]

[4.2]

[0.1]

(Foreign Exchange Gain/Loss included above)

[(0.4)]

[2.8]

[2.4]

[(3.7)]

[6.1]

Income (Loss) before Taxes

(36.8)

69.7

32.9

122.0

(89.1)

2

Net Income (Loss) from

(39.9)

62.6

22.7

69.7

(47.0)

Continuing Operations

Net Income from Discontinued Operations *3

-

-

-

16.9

(16.9)

Net Income (Loss)

(39.9)

62.6

22.7

86.6

(63.9)

Net Income (Loss) Attributable to Owners of the Parent

(49.7)

42.1

(7.6)

54.1

(61.7)

-

Net Income (Loss) Attributable to Non-Controlling Interests

9.8

20.5

30.3

32.5

(2.2)

*1 Share of profit of associates and joint ventures included.

1.1

11.8

12.9

13.4

(0.5)

*2 Discontinued operations are not included.

*3 Figures for FY2019, include ¥15.8 billion from gain on share exchanges after tax.

Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring

factors (losses incurred by business withdrawal and streamlining, etc.).

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Mitsubishi Chemical Holdings Corporation published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 12:29:13 UTC.